Comparison 1. Monoamine oxidase B inhibitors versus control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Deaths at end of follow up (FU)	12	2430	Odds Ratio (M‐H, Random, 95% CI)	1.12 [0.90, 1.41]
1.1 Selegiline ‐ levodopa from outset	5	926	Odds Ratio (M‐H, Random, 95% CI)	1.25 [0.91, 1.71]
1.2 Selegiline ‐ no levodopa at outset	7	1226	Odds Ratio (M‐H, Random, 95% CI)	1.03 [0.73, 1.44]
1.3 Lazabemide ‐ no levodopa at outset	1	278	Odds Ratio (M‐H, Random, 95% CI)	0.47 [0.08, 2.65]
2 Parkinsonian impairment ‐ mean change in UPDRS motor score from baseline to 1 year	5	1305	Mean Difference (IV, Random, 95% CI)	‐3.79 [‐5.30, ‐2.27]
2.1 Selegiline ‐ levodopa from outset	2	176	Mean Difference (IV, Random, 95% CI)	‐4.12 [‐6.58, ‐1.65]
2.2 Selegiline ‐ no levodopa at outset	3	810	Mean Difference (IV, Random, 95% CI)	‐4.57 [‐5.70, ‐3.44]
2.3 Lazabemide ‐ no levodopa at outset	1	319	Mean Difference (IV, Random, 95% CI)	‐1.35 [‐3.09, 0.39]
3 Parkinsonian impairment ‐ UPDRS motor scores at 1 year FU	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.1 Selegiline ‐ levodopa from outset	2		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Selegiline ‐ no levodopa at outset	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4 Parkinsonian disability ‐ mean change in UPDRS ADL score from baseline to 1 year	5	1306	Mean Difference (IV, Random, 95% CI)	‐1.49 [‐2.49, ‐0.49]
4.1 Selegiline ‐ levodopa from outset	2	176	Mean Difference (IV, Random, 95% CI)	‐1.54 [‐3.77, 0.68]
4.2 Selegiline ‐ no levodopa at outset	3	811	Mean Difference (IV, Random, 95% CI)	‐2.24 [‐2.85, ‐1.62]
4.3 Lazabemide ‐ no levodopa at outset	1	319	Mean Difference (IV, Random, 95% CI)	‐0.47 [‐1.31, 0.37]
5 Parkinsonian disability ‐ UPDRS ADL scores at 1 year FU	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
5.1 Selegiline ‐ levodopa from outset	2		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Selegiline ‐ no levodopa at outset	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6 Mean change in UPDRS total score from baseline to end of washout	3	429	Mean Difference (IV, Random, 95% CI)	‐3.15 [‐5.48, ‐0.82]
6.1 Selegiline	2	223	Mean Difference (IV, Random, 95% CI)	‐4.00 [‐6.49, ‐1.52]
6.2 Lazabemide	1	206	Mean Difference (IV, Random, 95% CI)	‐1.12 [‐4.95, 2.71]
7 Participants requiring levodopa	7		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 Follow up about 1 year	4	1138	Odds Ratio (M‐H, Random, 95% CI)	0.48 [0.37, 0.62]
7.2 At end of follow up	4	293	Odds Ratio (M‐H, Random, 95% CI)	0.50 [0.18, 1.38]
8 Development of motor fluctuations	6	1461	Odds Ratio (M‐H, Random, 95% CI)	0.73 [0.58, 0.91]
8.1 Selegiline ‐ levodopa from outset	3	761	Odds Ratio (M‐H, Random, 95% CI)	0.67 [0.49, 0.91]
8.2 Selegiline ‐ no levodopa at outset	3	700	Odds Ratio (M‐H, Random, 95% CI)	0.72 [0.44, 1.17]
9 Development of dyskinesias	5	1362	Odds Ratio (M‐H, Random, 95% CI)	0.96 [0.76, 1.22]
9.1 Selegiline ‐ levodopa from outset	2	662	Odds Ratio (M‐H, Random, 95% CI)	0.98 [0.71, 1.34]
9.2 Selegiline ‐ no levodopa at outset	3	700	Odds Ratio (M‐H, Random, 95% CI)	0.95 [0.66, 1.36]
10 Subjects with adverse events	6	847	Odds Ratio (M‐H, Random, 95% CI)	1.45 [1.04, 2.02]
10.1 Selegiline ‐ levodopa from outset	2	263	Odds Ratio (M‐H, Random, 95% CI)	1.52 [0.83, 2.78]
10.2 Selegiline ‐ no levodopa at outset	3	263	Odds Ratio (M‐H, Random, 95% CI)	1.26 [0.56, 2.85]
10.3 Lazabemide	1	321	Odds Ratio (M‐H, Random, 95% CI)	1.37 [0.79, 2.39]
11 Nausea	8	1436	Odds Ratio (M‐H, Random, 95% CI)	1.76 [1.10, 2.82]
11.1 Selegiline ‐ levodopa from outset	2	267	Odds Ratio (M‐H, Random, 95% CI)	2.19 [0.83, 5.80]
11.2 Selegiline ‐ no levodopa at outset	6	1169	Odds Ratio (M‐H, Random, 95% CI)	1.57 [0.86, 2.84]
12 Withdrawals due to adverse events	8	1479	Odds Ratio (M‐H, Random, 95% CI)	1.72 [0.98, 3.01]
12.1 Selegiline ‐ levodopa from outset	3	799	Odds Ratio (M‐H, Random, 95% CI)	2.52 [1.03, 6.14]
12.2 Selegiline ‐ no levodopa at outset	4	359	Odds Ratio (M‐H, Random, 95% CI)	1.23 [0.59, 2.54]
12.3 Lazabemide ‐ no levodopa at outset	1	321	Odds Ratio (M‐H, Random, 95% CI)	1.41 [0.40, 4.98]
13 Total withdrawals	11	2410	Odds Ratio (M‐H, Random, 95% CI)	0.95 [0.78, 1.17]
13.1 Selegiline ‐ levodopa from outset	4	848	Odds Ratio (M‐H, Random, 95% CI)	0.90 [0.66, 1.23]
13.2 Selegiline ‐ no levodopa at outset	7	1241	Odds Ratio (M‐H, Random, 95% CI)	1.14 [0.83, 1.57]
13.3 Lazabemide ‐ no levodopa at outset	1	321	Odds Ratio (M‐H, Random, 95% CI)	0.62 [0.30, 1.29]